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I
n 2003, the President of the United States introduced
a now often used phrase into the American lexicon,
“Mission accomplished” (1). While history has not
judged, to the greatest of degrees, his proclamation
with favor in terms of its accuracy, the idiom does seem
a ﬁtting response to the letter by Sanda and Greenbaum
(2), written in reaction to my editorial (3). This claim can
effectively be made as their action is exactly what I hoped
would occur: an open discourse.a debate, on how trials
to reverse type 1 diabetes are designed and performed. For
this, I am grateful and hope that more opinions such as
theirs come forward, both in written as well as verbal form
at scientiﬁc meetings, consistent with the stated goal of the
editorial (3).
To be clear, my intention was not to convey a message
that placebo-controlled trials should be outright discarded
without discussion, but rather that the concept of trial
design, including those involving either a universal control
or an adaptive trial design, be subject to more active
consideration rather than our just continuing the ways of
history because, as so much of life operates, “It has always
been done this way.” To my belief, each of the contrarian
arguments noted in the letter by Sanda and Greenbaum (2)
were, in fact, presented within the editorial (3)—notions
placed into the prose for the purpose of providing in-
tellectual balance. Yet, in the end, if the intended degree
for my providing a balanced viewpoint was inadequate, the
letter of Sanda and Greenbaum will, hopefully, address any
such shortcoming.
Finally, I join with these authors (2), as noted in the
editorial (3), that efforts like the National Institutes of
Health (NIH) TrialNet are without question advancing the
pace of clinical trials. I also acknowledge this issue of trial
design is not new to that group, having been subject to
previous consideration by them. Also as noted in my edi-
torial (3), the model should be tested, and NIH TrialNet
would certainly be in an ideal position to test it. That being
said, I remain conﬁdent in my belief that the number of
subjects making their way into such research trials rep-
resent the vast minority of persons in the U.S. eligible for
these efforts based on typical entry criteria. Hence, I would
once again portend that we need to explore new avenues
and novel thought processes routinely and often to in-
crease recruitment.and not for the matter of mere emo-
tions but because we must do a better job at what we do.
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